Skip to main content

Sponsored by Lilly

Did You Know? Beyond the Data

Did You Know? Beyond the Data

CDK4/6 Inhibitors for Treatment of High-Risk, HR-Positive/HER2-Negative Early Breast Cancer: Addressing Tolerability to Maximize Treatment Persistence
We are pleased to announce Part 2 of the new 2-part series, Did You Know? Beyond the Data. Our second article, with video commentary by Hope Rugo, MD, and an accompanying infographic, presents clinical data and real-world evidence on treatment patterns and tolerability considerations for CDK4/6 inhibitors in patients with early breast cancer with high risk of recurrence. We invite you to explore this informative series, designed to empower healthcare professionals with actionable insights to improve patient outcomes. Read More ›
The Impact of Underutilizing Adjuvant CDK4/6 Inhibitors in Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer
We are pleased to announce a new 2-part series, Did You Know? Beyond the Data. This article, with video commentary by Hope Rugo, MD, and an accompanying infographic, provides the latest clinical data and real-world evidence for consideration when treating early breast cancer patients with high risk of recurrence. We invite you to explore this informative series, designed to empower healthcare professionals with actionable insights to improve patient outcomes. Read More ›